Loading...
•
Dec 31, 2023
Aytu BioScience Q2 2024 Earnings Report
Aytu BioScience reported record ADHD revenue and operating income.
Key Takeaways
Aytu BioScience, Inc. reported a net revenue of $22.9 million for Q2 2024, with operating income reaching $2.4 million, marking the company's first quarter of positive operating income. The ADHD Portfolio revenue increased by 49% year-over-year to $16.6 million. Net loss for the quarter was $0.2 million, or $0.04 per share.
Consolidated net revenue was $22.9 million.
ADHD Portfolio net revenue increased 49% to $16.6 million.
Consolidated operating income was $2.4 million.
Net loss was $0.2 million, or $0.04 per share.
Revenue by Segment
Forward Guidance
Aytu BioPharma is focused on maximizing the potential of its Rx brands and continuing to drive improvement in long-term stockholder value. The company expects to see further operational improvements throughout calendar year 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...